Compare KMB & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMB | RMD |
|---|---|---|
| Founded | 1910 | 1989 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Containers/Packaging | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 32.2B |
| IPO Year | 1994 | N/A |
| Metric | KMB | RMD |
|---|---|---|
| Price | $95.37 | $208.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $113.54 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.33% | 1.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $16,447,000,000.00 | N/A |
| Revenue This Year | $3.83 | $10.60 |
| Revenue Next Year | $3.61 | $7.41 |
| P/E Ratio | $48.90 | ★ $25.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $92.42 | $198.64 |
| 52 Week High | $144.31 | $293.81 |
| Indicator | KMB | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 30.48 |
| Support Level | $92.42 | N/A |
| Resistance Level | $100.41 | $260.21 |
| Average True Range (ATR) | 2.10 | 5.46 |
| MACD | 0.09 | -1.28 |
| Stochastic Oscillator | 7.74 | 26.19 |
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.